All lobbying filings

Capitol Hill Consulting Group

Capitol Hill Consulting Group filed a Q4 termination report for Purdue Pharma LLP on January 20, 2026, reporting $50,000 in lobbying income.

Lobbying for Purdue Pharma LLP

As filed: CAPITOL HILL CONSULTING GROUP for PURDUE PHARMA LLP.

All filings by Capitol Hill Consulting Group · Everything Purdue Pharma LLP has reported

Filing · LD-2 quarterly report Q4 termination

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Representation ended

Dec 31, 2025

The registrant reported terminating its work for this client.

Official filing document

Lobbyists on this filing 3

BRIAN SUTTER

Previously held: Staff Dir., W&M Health Subcommittee, Chairman Dave Camp April, 2013 - Dec. 2014; Professional Staff, W&M Health Subcommittee, Chairman Dave Camp, Jan. 2011 - April 2013;Leg Dir., Rep. Dave Camp, May '08 - Jan.,'11 Leg Asst.Rep Camp, Feb '03-May'08;
EMILY ELIZABETH WILKINSON-HOLLAND New on this filing

Previously held: Staff -Rep. Price (2010-11), LA: Rep. Grimm (2011-12), Rep. Black (2012-13), Sen.Vitter (2013-2015), Sen. Heller (2015-17), Policy Adv. to the Sec.- Dept of HHS (3/2017-8/2017), Sr Advisor to Administrator - Ctrs for Medicare & Medicaid (8/17- 5/19)
CHRISTOPHER DAVIS New on this filing

Previously held: Staff Assistant, Legislative Assistant, Senior Legislative Assistant, and Legislative Director - Rep. Rick Boucher (2006-2011.

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Monitoring for issues and hearing related to prevention of abuse, misuse or diversion of prescription drugs; prescription drug payment reform; and pharmaceutical supply chain.

Bankruptcy

Monitored congressional efforts around the SACKLER Act.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.